Predict your next investment

Non-Profit Foundation
malariavaccine.org

See what CB Insights has to offer

Investments

1

Partners & Customers

6

About PATH Malaria Vaccine Initiative

PATH Malaria Vaccine Initiative is a program of PATH, an international nonprofit organization that drives transformative innovation to save lives and improve health, especially among women and children. MVI works with partners in private industry, government, and academia to develop malaria vaccines. Its major activities include establishing partnerships to manufacture and produce malaria vaccine candidates, evaluating and managing intellectual property issues to overcome or avoid commercial barriers to vaccine development, and developing clinical trial sites and conducting malaria vaccine clinical trials.

PATH Malaria Vaccine Initiative Headquarter Location

455 Massachusetts Avenue NW Suite 1000

Washington, DC, 20001,

United States

202822-0033

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest PATH Malaria Vaccine Initiative News

Catalent Biologics Announces Collaboration with Therachon Switzerland to Advance Clinical Development of Innovative Protein Therapy for Achondroplasia

May 15, 2017

Catalent Biologics Collaborates with PATH Malaria Vaccine Initiative to Create Antibodies for Malaria Vaccine Research and Development Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has signed an agreement with Therachon AG, a Swiss biotechnology company focused on rare genetic diseases, to support preclinical and clinical development of TA-46, a novel protein addressing achondroplasia, which is the most common form of short-limbed dwarfism. Under the agreement, Catalent Biologics has employed its proprietary GPEx® technology to produce different protein variants for Therachon, allowing them to screen multiple molecules and subsequently select their clinical candidate for further development. Catalent has been working with Therachon for more than a year to support the selection of the clinical candidate, and will now go on to manufacture cGMP material for a Phase I clinical study, scheduled for 2018. The project will be conducted at Catalent’s Madison, Wisconsin, biomanufacturing facility. “The work being carried out by Therachon’s team is truly innovative and could have a significant impact for those diagnosed with achondroplasia and suffering the associated complications,” commented Mike Riley, Vice President and General Manager of Catalent Biologics. “The development work undertaken by Catalent Biologics to support Therachon’s outstanding research has the potential to bring this potentially life-changing product to the market as quickly as possible.” Catalent’s proprietary GPEx technology creates stable, high-yielding mammalian cell lines with high speed and efficiency. The advantages of applying GPEx technology span from early feasibility studies, to clinical manufacturing, through to commercial scale production. To date, seven GPEx-based antibody and protein products are approved and marketed, and more than 40 therapeutic candidates are currently in the clinic across the world. Catalent’s facility in Madison, Wisconsin provides a full range of cell line development, process development, analytical and manufacturing services leveraging single use bioreactor systems. An expansion of the facility is underway, which will house a two 2,000 liter single use bioreactor configuration capable of producing 2,000 liter or 4,000 liter batches, and will be completed by October 2017. For more information on Catalent Biologics, visit http://www.CatalentBiologics.com Notes for Editors About Therachon AG Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. This rare genetic condition affects about one in 25,000 children and is caused by a genetic mutation of the FGFR3 receptor, which stunts child bone growth. Therachon is committed to translating the promise of its science into new treatments for patients with high unmet medical needs. For more information, visit http://www.therachon.com . Follow Therachon on Twitter and LinkedIn. About GPEx® technology Catalent performs GPEx programs at its commercial biomanufacturing facility in Madison, Wisconsin. Designed for flexible cGMP production from 10 L up to 1,000 liters, and non-GMP production up to 250 liters, the site features extensive single-use technologies and unidirectional flow to maximize efficiency and safety. Catalent recently announced the commencement of work to extend its Madison facility and add 22,000 square feet of space. About Catalent Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 10,000 people, including over 1,400 scientists, at more than 30 facilities across five continents, and in fiscal 2016 generated $1.85 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com More products. Better treatments. Reliably supplied.™ For the original version on PRWeb visit: http://www.prweb.com/releases/2017/05/prweb14332213.htm

PATH Malaria Vaccine Initiative Investments

1 Investments

PATH Malaria Vaccine Initiative has made 1 investments. Their latest investment was in Profectus BioSciences as part of their Unattributed on November 11, 2011.

CBI Logo

PATH Malaria Vaccine Initiative Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/16/2011

Unattributed

Profectus BioSciences

Yes

Date

11/16/2011

Round

Unattributed

Company

Profectus BioSciences

Amount

New?

Yes

Co-Investors

Sources

PATH Malaria Vaccine Initiative Partners & Customers

6 Partners and customers

PATH Malaria Vaccine Initiative has 6 strategic partners and customers. PATH Malaria Vaccine Initiative recently partnered with CMC Biologics on August 8, 2015.

Date

Type

Business Partner

Country

News Snippet

Sources

8/12/2015

Partner

Denmark

CMC Biologics, PATH Malaria Vaccine Initiative sign agreement for development of specific monoclonal antibodies

CMC Biologics , a global leader in clinical and commercial development and contract manufacture of therapeutic proteins , announced today it has entered into an agreement with the PATH Malaria Vaccine Initiative for process development and manufacture of specific monoclonal antibodies to test for their capacity to protect humans from malaria infection .

1

1/7/2013

Partner

United States

Subscribe to see more

Subscribe to see more

10

8/16/2012

Partner

United Kingdom

Subscribe to see more

Subscribe to see more

10

2/15/2011

Partner

United States

Subscribe to see more

Subscribe to see more

10

3/23/2009

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

8/12/2015

1/7/2013

8/16/2012

2/15/2011

3/23/2009

Type

Partner

Partner

Partner

Partner

Partner

Business Partner

Country

Denmark

United States

United Kingdom

United States

United States

News Snippet

CMC Biologics, PATH Malaria Vaccine Initiative sign agreement for development of specific monoclonal antibodies

CMC Biologics , a global leader in clinical and commercial development and contract manufacture of therapeutic proteins , announced today it has entered into an agreement with the PATH Malaria Vaccine Initiative for process development and manufacture of specific monoclonal antibodies to test for their capacity to protect humans from malaria infection .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.